Sprint Bioscience AB (publ) reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was SEK 0.018 million. Revenue was SEK 0.024 million compared to SEK 0.012 million a year ago. Net loss was SEK 17.91 million compared to SEK 13.92 million a year ago. Basic loss per share from continuing operations was SEK 0.45 compared to SEK 0.6 a year ago.
For the six months, sales was SEK 0.063 million compared to SEK 0.035 million a year ago. Revenue was SEK 0.078 million compared to SEK 0.419 million a year ago. Net loss was SEK 32.11 million compared to SEK 27.61 million a year ago. Basic loss per share from continuing operations was SEK 0.81 compared to SEK 1.22 a year ago.